filmov
tv
MRD evaluation: how, when and for which goal?
Показать описание
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the importance of using measurable residual disease (MRD) to guide therapy in multiple myeloma, and further explains how monitoring disease progression with MRD is the best way to ensure that patients are provided with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
MRD evaluation: how, when and for which goal?
MRD Assessment and Treatment Tailoring
MRD assessment: NGS vs. flow cytometry
Methods to evaluate MRD in AML
MRD Assessment and its Clinical Implications in AML
MRD Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial
MRD evaluation by MFC and NGS for MM
MRD evaluation in myeloma: The future is here
How is MRD testing done?
The importance of MRD assessment in all phases of ALL treatment
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
MRD Evaluation in Myeloma: A necessary clinical tool?
MRD assessment and the treatment of patients in the 'real world'
Measuring MRD: methods and challenges
Role of MRD Assessment in Multiple Myeloma
Technical tips for reliable MRD assessment in patients with multiple myeloma
MRD evaluation in clinical practice for MM
Ultra-sensitive assessment of MRD in peripheral blood of patients with multiple myeloma using NGF
MRD in AML: What is it and what do I do about it?
MRD Assessment and Consolidation in AML
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies
MRD evaluation using flowcytometry
